ArticleJournal of healthcare engineering2022
Molecular Characteristics and Prognostic Role of MFAP2 in Stomach Adenocarcinoma.
Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- MFAP2 promotes metastasis and drug resistance by regulating epithelial-to-mesenchymal transition through EGFR signaling pathway in colorectal cancer cells.Genes & diseases · 2026Article
- The role of microfibrillar-associated protein 2 in cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular characteristics and prognostic role of MFAP2 were by no means stated. The MFAP2 expression and prognostic prices in this study, with Cox analysis, was employed to develop a predictive fee for MFAP2. To know about coexpression and practical networks associated with MFAP2, LinkedOmics and GEPIA2 have been used. MFAP2 expression has been increased and verified in many unbiased coalitions in TCGA-STAD tumor tissues. In addition, in each TCGA and various cohorts, increased MFAP2 was linked with lower survival. Evaluation by Cox revealed the unbiased danger to average survival, disease-specific survival, and progression-free survival of STAD used to be due to the elevated expression of MFAP2. Active community assessed the MFAP2, through which more than a few cancer-associated kinases and E2F household pathways are regulated, which shows that MFAP2 affects RNA transportation, oocyte meiosis, spliceosome, and ribosome biogenesis. MFAP2 can predict and is linked to the prediction of STAD independently. The closure of the MFAP2 link to the macrophage marker genes is, in particular, the achievable core of immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.